Literature DB >> 3325854

Grafting genetically modified cells to the brain: possibilities for the future.

F H Gage1, J A Wolff, M B Rosenberg, L Xu, J K Yee, C Shults, T Friedmann.   

Abstract

Diagnostic and therapeutic approaches to disorders of the central nervous system (CNS) are particularly difficult to develop because of the relative inaccessibility of the mammalian brain to study and chemical treatment, the complexity and interconnectedness of CNS subsystems, and the profound and continued lack of fundamental understanding of the relationship between structure and function in the CNS. Neural grafting in the CNS has recently suggested a potential approach to CNS therapy through the selective replacement of cells lost as a result of disease or damage. Independently, studies aimed at direct genetic therapy in model systems have recently begun to suggest conceptually new approaches to the treatment of several kinds of human genetic disease, especially those caused by single-gene enzyme deficiencies. We suggest that a combination of these two approaches, namely the grafting into the CNS of genetically modified cells, may provide a new approach toward the restoration of some functions in the damaged or diseased CNS. We present evidence for the feasibility of this approach, including a description of some current techniques for mammalian cell gene transfer and CNS grafting, and several possible approaches to clinical applications.

Entities:  

Mesh:

Year:  1987        PMID: 3325854     DOI: 10.1016/0306-4522(87)90159-x

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  19 in total

1.  The use of a retroviral vector to identify foetal striatal neurones transplanted into the adult striatum.

Authors:  P C Emson; S Shoham; C Feler; T Buss; J Price; C J Wilson
Journal:  Exp Brain Res       Date:  1990       Impact factor: 1.972

2.  Clinical application of somatic gene therapy in inborn errors of metabolism.

Authors:  F D Ledley
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

3.  Gene delivery to rat enteric neurons using herpes simplex virus-based vectors.

Authors:  M K Howard; R S Coffin; A R Maclean; S M Brown; D Bailey; P N Anderson; G Burnstock; D S Latchman
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

Review 4.  Gene transfer into the nervous system.

Authors:  X O Breakefield; A I Geller
Journal:  Mol Neurobiol       Date:  1987       Impact factor: 5.590

5.  Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

Authors:  J A Wolff; L J Fisher; L Xu; H A Jinnah; P J Langlais; P M Iuvone; K L O'Malley; M B Rosenberg; S Shimohama; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease.

Authors:  R J Mandel; K G Rendahl; S K Spratt; R O Snyder; L K Cohen; S E Leff
Journal:  J Neurosci       Date:  1998-06-01       Impact factor: 6.167

Review 7.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity.

Authors:  W F Goins; K A Lee; J D Cavalcoli; M E O'Malley; S T DeKosky; D J Fink; J C Glorioso
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 9.  Gene therapy for diseases of the nervous system.

Authors:  J Fick; M A Israel
Journal:  West J Med       Date:  1994-09

10.  Nerve growth factor beta(NGF beta) delivery via a collagen/hydroxyapatite (Col/HAp) composite and its effects on new bone ingrowth.

Authors:  A Letic-Gavrilovic; A Piattelli; K Abe
Journal:  J Mater Sci Mater Med       Date:  2003-02       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.